Volpara (ASX:VHT) share price pushes higher on record quarterly update

The company provided investors with its latest performance report.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Volpara Health Technologies Ltd (ASX: VHT) share price is climbing today following the release of the company's quarterly report.

At the time of writing, the healthcare technology company's shares are up 1.17% to $1.295.

a smiling doctor looks at her computer screen with medical imaging X-rays on a light screen in the background.

Image source: Getty Images

How did Volpara perform for Q2 FY22?

According to its release, Volpara advised record sales and cash inflows for the 3 months ending 30 September.

In particular, cash receipts from customers totalled NZ$7.1 million (A$6.79 million), an increase of 11% on the previous quarter. Compared against the prior corresponding period, this metric grew 52% — or 68% in constant currency terms.

Subscription-based receipts continued to accelerate, representing more than NZ$6.9 million (A$6.60 million) for the 3 months. This is a jump of 63% year-on-year, or roughly 74% in constant currency.

Net operating cash outflow came to NZ$3.8 million (A$3.63 million), consistent with Q2 FY21. Some material supplier contract renewals, such as its annual insurance program, kept the costs in line.

Volpara noted that it closed the quarter with cash of NZ$25 million (AS23.91) on hand and no debt.

On the Software-as-a-Service (SaaS) front, annual recurring revenue (ARR) stood at US$20.4 million (A$27.24) million. Contracts were signed across the company's full product suite as both standalone sales and platform deals. Many existing customers also increased contracts with Volpara whether by adding on products or expanding use of existing products.

The average revenue per user (ARPU) improved to US$1.46 (A$1.95), up 5% on the prior quarter. Its legacy MRS support contracts were heavily weighted towards the lower ARPU ranges, while its subscription-based products weighted more to the higher ARPUs.

Volpara group CEO Dr Ralph Highnam commented:

Q2 is traditionally our weakest quarter for sales, and yet today we've shown that we've had a record quarter not only for sales but also cash inflows.

…Our job now is to keep that momentum and passion for what we do as we go through the second half of the year, keeping in mind potential winter waves of COVID in the northern hemisphere.

Volpara share price summary

The past 12 months have been a disappointing run for investors, with the company's shares down almost 11%. When looking at year-to-date, its losses are hovering around 9% over the period.

Based on today's price, Volpara presides a market capitalisation of roughly $329 million and has approximately 251.3 million shares outstanding.

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of and has recommended VOLPARA FPO NZ. The Motley Fool Australia owns shares of and has recommended VOLPARA FPO NZ. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

Man sleeping with a sleep apnoea mask on.
Broker Notes

Down 22%! 3 reasons to buy the big dip in ResMed shares today

Two leading analysts deliver their verdicts on ResMed’s beaten-down share price.

Read more »

Portrait, confidence and team of doctors in the hospital standing after a consultation or surgery. Success, healthcare and group of professional medical workers in collaboration at a medicare clinic.
Healthcare Shares

ASX healthcare shares have jumped 21% since June. Can the recovery continue?

Can ASX healthcare shares can sustain their recovery?

Read more »

Donor donates blood in medical clinic. Beautiful European woman of 30 years sits in medical chair looking into camera and smiling.
Healthcare Shares

After losing half their value, can CSL shares reclaim $275?

A rebound is here, but can it last? Here's what the experts think.

Read more »

A man wearing a white coat holds his hands up and mouth open with joy.
ASX Share Market News

Healthcare shares lead the ASX 200 again as sector rotation gathers pace

The sector is up 20% in just a month as value investors swoop on blue-chip favourites like CSL.

Read more »

A doctor shrugs and holds his hands out.
Healthcare Shares

CSL shares are up 25%: is it time to buy, hold or sell?

CSL's recovery could be well underway, but analysts remain far from convinced.

Read more »

Three people jumping cheerfully in clear sunny weather.
Healthcare Shares

This ASX biotech stock is tipped to double or even triple in value

Is this one of the ASX's most overlooked biotech opportunities?

Read more »

A woman leans forward with her hand behind her ear, as if trying to hear information.
Healthcare Shares

Cochlear shares have jumped 23% in a month: Is there more upside ahead?

Cochlear shares have erased part of their recent losses, but there is a long way to go until they return…

Read more »

A woman researcher holds a finger up in happiness as if making the 'number one' sign with a graphic of technological data and an orb emanating from her finger while fellow researchers work in the background.
Healthcare Shares

Up 55% in 2026! Why this ASX healthcare stock is climbing again

This ASX healthcare stock is extending its strong 2026 run.

Read more »